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Table 1. Effect of Anti c-Kit mAb on Peripheral Blood Cell Counts
Day 0
Control Day 2 Day 4 Day 7 Day 11
WBC 12.1 6.6 4.2 2.6 9.5
Hgb 15.1 14.5 13.2 6.2 5.3
ANC 796 180 32 26 320
Platelet Count 1107 1182 1098 763 220
Mice injected with 1 mg ACK-2 intravenously on Days 0, 2 & 4.
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EPITHELIAL CHIMERISM IN THE ORAL MUCOSA AFTER HUMAN HEMA-
TOPOIETIC CELL TRANSPLANTATION
Spyridonidis, A., Zeiser, R., Metaxas, Y., Faber, P., Finke, J. Freiburg
University Medical Center, Freiburg, Germany.
Several study groups have reported on a nonhematopoietic chi-
merism following allogeneic hematopoietic cell transplantation
(aHCT) both in animals and humans. We recently investigated this
phenomenon in humans and described the pitfalls of identiﬁcation
of epithelial chimerism (Spyridonidis et al, Am J Pathol 164:1147–
1155, 2004). The purpose of the present study was to examine
epithelial chimerism in single cells isolated from the oral mucosa.
Buccal scrapings obtained from 13 female patients who underwent
a sex-mismatched aHCT were employed to prepare cytospins. The
examination was performed 75–1964 days after aHSCT. At this
time point, no patient had signs of mucositis or oral GvHD.
Cytospin preparations were examined with a combination of FISH
for the Y or the XY chromosome; immunoﬂuorescent stain for the
epithelial-speciﬁc marker cytokeratin (CK), for CD45, and Drag
cell nuclei stain; with APAAP immunocytochemistry using either
CD15-, CD45-, CD68-, or CD3-speciﬁc antibodies; and with
hematoxylin and eosin (HE) staining. Evaluation of epithelial chi-
merism was performed with laser scanning confocal microscopy
from examiners who were not aware of the patients’ present or past
medical history. CD45 or CD3 cells were found in 4 patients
with a frequency of  1%. No CD68 or CD15 positive mac-
rophages were detected. In the FISH-Y combined stains, we de-
tected Y/CK/CD45 cells in 12 of 13 patients (92%), with a
mean of 1.8% Y/CK/CD45 cells per 200 total cells analyzed
(range, 0.5%-7.3%). The identiﬁed Y/CK/CD45 cells were
counterstained with HE and revealed an epithelial morphology.
Screening of 5 patients with XY stain demonstrated all Y cells of
them having only 1 X chromosome, making fusion as the under-
lying mechanism unlikely. We retrospectively reviewed the trans-
plantation documents of every patient and found a signiﬁcant
correlation (P value  .0028) between the severity of mucositis in
the early posttransplantation period (up to day 30) and the
degree of epithelial chimerism found at later time points (days
75- 1964), where no signs of mucositis were present. We
conclude that epithelial chimerism of the oral mucosa is a real
phenomenon after aHSCT. Further molecular investigation on a
single-nucleus level and analysis of greater number of transplanted
patients are needed to understand the underlying mechanisms
responsible for generation of the donor derived epithelial cells.
Tissue injury seems to play a role in these mechanisms.
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PEGFILGRASTIM VERSUS FILGRASTIM TO ACCELERATE HEMATOPOI-
ETIC RECOVERY AFTER HIGH-DOSE MELPHALAN AND AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) FOR MULTI-
PLE MYELOMA
Olin, R.L., Luger, S.M., Porter, D.L., Schuster, S.J., Tsai, D.,
Nasta, S., Perl, A., Loren, A.W., Goldstein, S., Mangan, P., Sherry, V.,
Cunningham, K., Sachs, B., Hummel, K., Stadtmauer, E.A. Bone
Marrow and Stem Cell Transplant Program, University of Pennsylva-
nia, Philadelphia, PA.
High-dose melphalan followed by ASCT is a common compo-
nent of the early treatment for multiple myeloma. Daily subcuta-
neous injections of ﬁlgrastim (Neupogen) at 5 g/kg/day until
ANC  500/L are routinely administered at our center from day
4 following ASCT, to accelerate hematopoietic recovery and
lessen neutropenic complications. Pegﬁlgrastim (Neulasta) as a
single 6-mg ﬁxed dose via subcutaneous injection has been shown
to have similar efﬁcacy and ease of use as ﬁlgrastim in the non-
transplantation setting, but little data are available in the transplan-
tation setting. We began using pegﬁlgrastim on day 1 following
ASCT for patients with multiple myeloma and performed a retro-
spective cohort study comparing those who received ﬁlgrastim (the
ﬁlgrastim group [FG]; n  6) with those who received pegﬁlgras-
tim (the pegﬁlgrastim group [PG]; n  11). Transplantations
occurred between July 2002 and January 2004 and included all
patients transplanted for myeloma in that period for whom sufﬁ-
cient data were available. All patients had peripheral stem cells
harvested after cytoxan/ﬁlgrastim mobilization. Main outcome
measures were days from stem cell infusion to WBC nadir, days to
ANC  500/L, and days to ANC  1000/L. Subjects were
excluded if CBCs were drawn less often than every 4 days. There
were no signiﬁcant differences between the FG and the PG with
respect to the following variables: age, gender, hemoglobin, creat-
inine, calcium, albumin, beta-2 microglobulin, number of prior
lines of therapy, and number of CD34 cells infused. After trans-
plantation, the median number of days to WBC nadir was 7 (range,
5–9) in the FG and 6 (range, 5–8) in the PG (P  .31). However,
median number of days to ANC 500/L was 11.5 (range, 11–17)
in the FG and 10 (range, 9–12) for the PG (P  .02). Similarly,
median number of days to ANC  1000/L was 12 (range, 11–17)
for the FG and 11 (range, 10–13) for the PG (P  .03). Five of 6
patients in the FG had neutropenic fever after transplantation,
compared with 5 of 11 patients in the PG (P  .30). Currently, no
signiﬁcant differences in infection or relapse rates between the
groups was noted, and there were no deaths in either group. In this
retrospective cohort study, pegﬁlgrastim was safe and at least
equivalent to ﬁlgrastim for accelerating hematopoiesis after ASCT
for multiple myeloma. Furthermore, there was no signiﬁcant dif-
ference in the incidence of neutropenic fever, infection, and sur-
vival, suggesting a similar clinical utility.
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VANGANCICLOVIR PROPHYLAXIS FOR THE PREVENTION OF CYTO-
MEGALOVIRUS REACTIVATION AND DISEASE IN ALLOGENEIC STEM
CELL TRANSPLANTATION RECIPIENTS
Magalhaes-Silverman, M., Carter, T., Hohl, R., Shamsuddin, H.,
Gingrich, R. University of Iowa, Iowa City, IA.
Background: CMV infection continues to be an important cause
of morbidity and mortality after allogeneic stem cell transplanta-
tion. Valganciclovir (VGC), the valine ester of ganciclovir, has
excellent oral bioavailability and has the potential to replace intra-
venous ganciclovir in many situations, namely CMV prophylaxis or
preemptive therapy after allogeneic transplantation. Methods:
From October 2002 to April 2004, 34 patients who were either
CMV seropositive or had a seropositive donor were enrolled in
prospective trial of intravenous (IV) ganciclovir at 5 mg/kg twice a
day for 1 week, followed by oral VGC 900 mg twice a day for a
total of 180 days. IV ganciclovir was started at time of engraftment.
Dose adjustments of VCG were made according to renal function,
and growth factors were allowed in the event of neutropenia. Study
endpoints included incidence of CMV reactivation and disease
during the ﬁrst 180 days after transplantation. For the study,
viremia was deﬁned as a positive CMV blood culture by shell vial
or conventional culture. A positive antigenemia assay in patients
with severe (grade III-IV) GVHD was deﬁned as 1 positive cell on
either of 2 duplicate slides. For patients with no or mild GVHD
(grade I-II), a positive antigenemia assay was deﬁned as 2 positive
cells/slide. Results: Thirty-four patients were enrolled. Thirteen
patients were not able to proceed after consenting due to positive
antigenemia prior to starting study (3 patients), ﬁnancial reasons (3
patients), severe gut GVHD unabling oral intake (5 patients), or
death (2 patients). Of those who received VGC, the median age
Poster Session II
87BB&MT
was 49 years (range, 21–71 years). Ten patients underwent a sibling
transplantation (5 standard regimen, 5 reduced intensity), and 11
underwent an unrelated transplantation (5 standard regimen, 6
reduced intensity); graft T-cell depletion was done in 15 patients
(Campath-1H in 7, OKT3 in 8). Neutropenia was observed in 5
patients, resolving in all of them. VGC was discontinued tempo-
rarily in these 5 patients until they recovered from neutropenia.
Four of them received concomitant mycophenolate mofetil. No
adverse effects were otherwise reported. The median follow-up
after transplantation is 12 months. Six patients died during the
study, from disease progression (2 patients), fungal infection (1
patient), or GVHD (3 patients). None of the 21 patients experi-
enced CMV reactivation or disease while on VGC. Conclusions:
These early results suggest that VGC has a role in the posttrans-
plantation setting, and that further evaluation of VGC in CMV
prophylaxis or preemptive therapy is needed.
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ACTUALIZING A WELLNESS PROGRAM AND WELLNESS ROOM IN THE
ONCOLOGY SETTING: GETTING A PROGRAM THROUGH A LARGE IN-
STITUTION
Galgay, L., Swift, S., Cusack, G., Jones-Wells, A., Rivera, P.,
Chisholm, L. The National Institutes of Health, Bethesda, MD.
The Clinical Center (CC) of the National Institutes of Health
(NIH) is a hospital solely dedicated to conducting biomedical
research. Participation in the rigors of a phase I or II clinical trial
requires inner strength, support, and ability to follow through with
the demands of research. Nurses on the Oncology, Experimental
Transplantation Unit at the CC acknowledge the special needs of
their patients, caregivers, and staff, and strive to ﬁnd ways to lessen
the impact of these demands. A group of oncology nurses at the
CC formed a Complementary and Alternative Medicine (CAM)
Cancer Nursing Interest Group. A review of the literature reveals
that a focus on patients’ psychological, social, physical, and spiri-
tual needs promotes improved quality of life in oncology patients.
The CAM Interest Group recognized the importance of integra-
tive therapies as one strategy to assist patients in dealing with their
chronic illness. This presentation outlines the development and
inception of a wellness program to aid patients in dealing with
chronic illness using integrative therapies such as relaxation ther-
apy, guided imagery, and a “room for silence.”
The “plan-do-check-act” model serves as our conceptual model
for development and evaluation of the program. Benchmarking
with preeminent institutions nationwide, and identiﬁcation of key
stakeholders within the institution, as well as the National Cancer
Institute (NCI) and the National Center for Complementary and
Alternative Medicine (NCCAM), was instrumental in the develop-
ment of the program.
With visionary nursing leadership and extensive collaboration
with the CC interdisciplinary team, the program has been incor-
porated and follows the credentialing guidelines proposed by the
CC’s Integrative Medicine Taskforce. Self-care, empowerment,
healing versus curing, relaxation, and comfort are emphasized, and
an examination of theories and models is used for health education
and promotion. Dedicated space has been allocated for a “room for
silence,” which is designed for meditation, prayer, imagery, and
journaling. Patients and staff evaluate the wellness program on an
ongoing basis and changes are incorporated based on feedback.
Incorporating a wellness program fosters improved patient out-
comes, enhances quality of life for oncology patients, and serves as
a model for integrative care.
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URSODIOL-BASED PROPHYLAXIS FOR VENO-OCCLUSIVE DISEASE
(VOD): A RETROSPECTIVE RISK-BASED REVIEW OF OUTCOMES FOL-
LOWING ALLOGENEIC STEM CELL TRANSPLANTATION
Thompson, J.M., Akard, L.P., Dugan, M.J., English, K., Jansen, J.
Indiana Blood & Marrow Transplantation, Indianapolis, IN.
A total of 307 sequential patients allografted at our institution
over the past decade were evaluated retrospectively to study treat-
ment-related hepatotoxicity, and prevention thereof, following the
use of various ursodiol-based VOD prophylaxis regimens. The
patient group comprised 178 males and 129 females, median age 42
years. There were 227 related and 80 unrelated donors, 271
matched and 36 mismatched. Diagnoses included acute leukemia
in 129 patients (42%), chronic leukemia in 89 patients (29%),
lymphoma in 37 patients (12%), myelodysplasia in 21 patients
(7%), myeloma in 15 patients (5%), aplastic anemia in 10 patients
(3%), and other in 6 patients (2%). A total of 158 patients (51%)
received TBI, 112 patients (36%) received busulfan, and 37 pa-
tients (12%) received methotrexate. All patients whose bilirubin
exceeded 2.0 mg/dL postgrafting (166 patients; 54%) were evalu-
ated for cause. The mean day (D) of maximal bilirubin elevation for
this group was D19. Non-VOD causes included regimen-related
toxicity in 57 patients (34%), GVHD in 50 patients (30%), infec-
tion/sepsis/multiorgan dysfunction in 19 patients (12%), and
ABO-realted hemolysis in 18 patients (11%). The diagnosis of
VOD was made by criteria described previously. VOD accounted
for the cause of hyperbilirubinemia in 23 patients in this subset of
166 patients (14%). Of the total group of 307 patients, 164 patients
(53%) received VOD prophylaxis, 38 patients (23%) received oral
ursodiol (Urso) alone (600–900 mg/day), 69 patients (42%) re-
ceived IV Urso  heparin (Hep)(800 U/hr), 54 patients (33%)
received SQ Urso  Lovenox (Lov)(40 mg/day), and 3 patients
(2%) received Hep alone. Overall, 23 patients (7.5%) developed
VOD, with only 7 patients dying due to VOD (2.3%). The inci-
dence of VOD was not signiﬁcantly different for / Urso (7.5%
vs 7.6%), / Lov (7.4% vs 7.5%), / Hep (11.1% vs 6.4%;
P  .18); / Urso  Lov (7.4% vs 7.5%), and / Urso Hep
(7.2% vs 7.6%). Data were also analyzed for the effect of 7 known
risk factors for VOD: age  40 years, unrelated donor, preparative
regimen including busulfan or TBI, baseline AST, methotrexate
for GVHD prophylaxis, and history of liver disease. Risk factors (f)
for VOD occurred as follows: 0(f), 5 (2%); 1(f), 90 (29%); 2(f), 150
(49%); 3(f), 54 (17%); 4(f), 8 (3%). The occurrence of VOD (%)
correlated with the number of risk factors (f) pregrafting: 0(f), 0/5
(0%); 1(f), 5/90 (6%); 2(f), 10/150 (7%); 3(f), 7/54 (13%); 4(f), 1/8
(12%). The overall incidence of VOD, and related death, is lower
in this series than historical reports. The beneﬁt of ursodiol-based
prophylactic regimens appears to be greatest in patients with 2 or
fewer VOD-related risk factors.
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VORICONAZOLE (VOR) IS SAFE AND EFFECTIVE AS PROPHYLACTIC ANTI-
FUNGAL THERAPY FOR ALLOGENEIC STEM CELL TRANSPLANTATION (AT)
Martin, T.1, O’Malley, R.2, Working, M.2, Guglielmo, J.1,
Fischbach, N.1, Damon, L.1, Navarro, W.1, Kaplan, L.1, Linker, C.1
1University of California, San Francisco, San Francisco, CA; 2Wake
Forest Medical School, Winston Salem, NC.
Background: Despite ﬂuconazole (FLU) prophylaxis in AT,
invasive fungal infection (IFI) continues to cause signiﬁcant mor-
bidity and mortality. VOR is a second-generation triazole with
broad-spectrum activity. Since August 2002, VOR has been used as
antifungal prophylaxis at UCSF Medical Center. The goals of this
study were to evaluate the incidence of IFI up to d100 and assess
safety and organ toxicity (OT). Methods: The records of patients
receiving VOR prophylaxis from August 2002 to May 2004 were
reviewed. Demographics, conditioning, stem cell source, HLA
status, laboratory and radiology results, OT, and survival were
analyzed. All patients were hospitalized throughout AT. Tacroli-
mus and MTX / MMF were used for GVHD prophylaxis.
VOR (4 mg/kg twice a day IV/PO) was administered through day
100 post-AT. EORTC criteria were used to assess for IFI.
Results: A total of 72 patients were identiﬁed (44 males and 28
females, mean age 54 years [range, 19–70]). Of these, 41 patients
received low-intensity conditioning and 31 received myeloablative
therapy. PBSCs were used more frequently than BM (60 vs 12).
Sibling donors were used for 37 patients; unrelated donors, for 35
patients. The 100- and 180-day TRM rates were 8% and 13%.
The incidence of grade II-IV aGVHD was 16%. Two patients
(3%) developed deﬁnitive IFI (1 mucor and 1 aspergillus plus
scedosporium). No probable IFIs were identiﬁed. Both patients
with deﬁnitive IFI died, 1 from grade IV GVHD and 1 from
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